ClinicalTrials.gg
Active, not recruitingNCT07037771Updated Aug 12, 2026

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

A Phase 3 interventional study of zodasiran Injection and Placebo in Homozygous Familial Hypercholesterolemia, sponsored by Arrowhead Pharmaceuticals. Active, not recruiting at 43 sites in 18 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Arrowhead Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.

02

Conditions studied

  • Homozygous Familial Hypercholesterolemia
03

In context

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

This study's enrollment of 70 is above the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.

Browse Homozygous Familial Hypercholesterolemia studies →

Lead sponsor

Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 12 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥12 years, non pregnant, non lactating, do not plan to become pregnant during the study
  • Body weight ≥35 kg at Screening as patients could theoretically be \<35 kg as the study continues.
  • HoFH based on a supportive genetic test or a clinical diagnosis (total cholesterol >500 mg/dL[13 mmol/L] OR treated LDL-C concentration of ≥300 mg/dL [≥8 mmol/L] either accompanied by TGs \<300 mg/dL [3.4 mmol/L] AND both parents with documented total cholesterol >250 mg/dL [6.5 mmol/L] OR cutaneous or tendinous xanthoma before 10 years of age)
  • LDL-C ≥70 mg/dL (1.8 mmol/L). For adolescents 12 to \<18 years of age, screening LDL-C ≥116 mg/dL (3 mmol/L).
  • (HbA1c) ≤9.5%
  • Total \<2xULN, unless in previously confirmed cases of Gilbert's syndrome
  • or aspartate aminotransferase \<3×
  • On standard of care, maximally tolerated lipid-lowering therapy to include a maximally tolerated statin, ezetimibe, and a PCSK9 inhibitor

Exclusion criteria

Exclusion Criteria:

  • Use of a hepatocyte-targeted siRNA within 365 days before Day 1 (except inclisiran, which is permitted; administration of inclisiran and study drug must be separated by at least 4 weeks)
  • Use of an antisense oligonucleotide molecule within 3 months before Day 1 (except inclisiran, which is permitted; administration of inclisiran and study drug must be separated by at least 4 weeks)
  • Use of evinacumab within 3 months before Day 1. Evinacumab use is prohibited during the study.
  • Non-response to evinacumab, defined as LDL-C reduction \<15% from baseline after 2 doses
  • Use of any other agent or device within 30 days or 5 half-lives (whichever is longer) before Day 1
  • Use of systemic (unless used as replacement therapy for pituitary/adrenal disease with a stable regimen)
  • Estimated \<30 mL/min

NOTE: Additional Inclusion/exclusion criteria may apply per protocol

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    zodasiran

    5 doses of zodasiran by subcutaneous (sc) injection (randomized period). 4 or 5 doses of zodasiran by sc injection (optional open-label period).

    Drug: zodasiran Injection

  • Placebo comparator
    Placebo

    Calculated volume to match active treatment by sc injection (randomized period). 4 or 5 doses of zodasiran by sc injection (optional open-label period)

    Drug: zodasiran Injection · Drug: Placebo

Interventions

  • ARO-ANG3 Injection

    Also known as: ARO-ANG3

  • DrugPlacebo

    sterile normal saline (0.9% NaCl)

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline to Month 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) (Randomized period)

    Time frame: Baseline, Month 12

Secondary outcomes

  1. Change and Percent Change from Baseline to Month 12 in Fasting Apolipoprotein B (ApoB) (Randomized Period)

    Time frame: Baseline, Month 12

  2. Change and Percent Change from Baseline to Month 12 in Fasting Non-High Density Lipoprotein Cholesterol (non-HDL-C) (Randomized Period)

    Time frame: Baseline, Month 12

  3. Change from Baseline to Month 12 in Fasting LDL-C (Randomized Period)

    Time frame: Baseline, Month 12

  4. Area Under the Plasma Concentration Versus the Time Curve (AUC) from Baseline to Month 12 for Fasting LDL-C (Randomized Period)

    Time frame: Baseline, Month 12

  5. Change and Percent Change from Baseline to Month 12 in Fasting Triglycerides (TGs) (Randomized Period)

    Time frame: Baseline, Month 12

  6. Change and Percent Change from Baseline to Month 12 in Fasting Angiopoietin-like Protein 3 (ANGPTL3) (Randomized Period)

    Time frame: Baseline, Month 12

  7. Change and Percent Change from Baseline to Month 12 in Fasting Total Cholesterol (Randomized Period)

    Time frame: Baseline, Month 12

  8. Change and Percent Change from Baseline to Month 12 in Fasting High-Density Lipoprotein Cholesterol (HDL-C) (Randomized Period)

    Time frame: Baseline, Month 12

  9. Proportion of Participants who Meet European Union (EU) LDL-C Apheresis Eligibility Criteria (per German Apheresis Working Group) at Month 12 (Randomized Period)

    Time frame: Month 12

  10. Proportion of Participants who Meet United States (US) Apheresis Eligibility Criteria (per National Lipid Association) at Month 12 (Randomized Period)

    Time frame: Month 12

  11. Proportion of Participants with Fasting LDL-C <100 mg/dL (2.6 mmol/L) at Month 12 (Randomized Period)

    Time frame: Month 12

  12. Change from Baseline in Fasting LDL-C Over Time (Randomized Period)

    Time frame: Baseline, Day 1, Months 1, 2, 3, 4.5, 6, 7.5, 9, 10.5, and 12

  13. Percent Change from Baseline in fasting LDL-C Over Time (Randomized Period)

    Time frame: Baseline, Day 1, Months 1, 2, 3, 4.5, 6, 7.5, 9, 10.5, and 12

  14. Percent Change from Baseline to Month 12 in Fasting Lipoprotein(a) [Lp(a)] (Randomized Period)

    Time frame: Baseline, Month 12

07

Study locations

43 sites
  • Research Site 7
    Park Ridge, Illinois 60068, United States
  • Research Site 2
    New York, New York 10029, United States
  • Research Site 1
    Cincinnati, Ohio 45227, United States
  • Research Site 14
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site 13
    Camperdown, New South Wales 2050, Australia
  • Research Site 9
    Saint Leonards, New South Wales 2065, Australia
  • Research Site 21
    Heidelberg, Victoria 3084, Australia
  • Research Site 3
    Nedlands, Western Australia 6009, Australia
  • Research Site 40
    Innsbruck, 6020, Austria
  • Research Site 39
    Linz, 4021, Austria
  • Research Site 42
    Vienna, 1090, Austria
  • Research Site 37
    Vienna, 1130, Austria
  • Research Site 33
    La Louvière, 7100, Belgium
  • Research Site 34
    Leuven, 3000, Belgium
  • Research Site 24
    Cerqueira César, São Paulo CEP-05403-000, Brazil
  • Research Site 5
    Vancouver, British Columbia V6Z 2H2, Canada
  • Research Site 6
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site 4
    Québec, G1V 4W2, Canada
  • Research Site 30
    Hradec Králové, General E3 500 0, Czechia
  • Research Site 23
    Paris, 75013, France
  • Research Site 17
    Tbilisi, 0159, Georgia
  • Research Site 18
    Tbilisi, 160, Georgia
  • Research Site 19
    Tbilisi, 186, Georgia
  • Research Site 35
    Berlin, 13353, Germany
  • Research Site 10
    Jerusalem, 9112001, Israel
  • Research Site 15
    Tel Litwinsky, 5265601, Israel
  • Research Site 26
    Kanazawa, Ishikawa-ken 920-8641, Japan
  • Research Site 27
    Suita, Osaka 564-8565, Japan
  • Research Site 20
    Fukushima, 960-1295, Japan
  • Research Site 16
    Okayama, 700-8558, Japan
  • Research Site 22
    Saitama, 350-0495, Japan
  • Research Site 25
    Tokyo, 113-8510, Japan
  • Research Site 12
    Christchurch, 8011, New Zealand
  • Research Site 31
    Riyadh, 12713, Saudi Arabia
  • Research Site 11
    Parktown, Johannesburg 2193, South Africa
  • Research Site 8
    Cape Town, 7925, South Africa
  • Research Site 43
    Barcelona, 8907, Spain
  • Research Site 28
    Córdoba, 14004, Spain
  • Research Site 29
    Madrid, 28041, Spain
  • Research Site 32
    Gothenburg, 413 46, Sweden
  • Research Site 36
    Afyonkarahisar, 03200, Turkey (Türkiye)
  • Research Site 41
    Bornova/Izmir, 35100, Turkey (Türkiye)
  • Research Site 38
    Melikgazi/Kayseri, 38030, Turkey (Türkiye)
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Aug 2027, 26 months after the start.

Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's planned 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jun 25, 2025
StartActual
Jun 17, 2025
Primary completionEst.
Aug 20, 2027
CompletionEst.
Aug 20, 2027
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07037771
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Jun 17, 2025
Primary completion
Aug 20, 2027 (estimated)
Completion
Aug 20, 2027 (estimated)
Last update
Aug 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zodasiran

Start the discussion